P017 Abemaciclib + endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes
Titel:
P017 Abemaciclib + endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes
Auteur:
Johnston, S. Toi, M. O’Shaughnessy, J. Rastogi, P. Campone, M. Neven, P. Huang, C.S. Huober, J. Jaliffe, G. Garnica Cicin, I. Tolaney, S. Goetz, M.P. Rugo, H. Senkus, E. Testa, L. Del Mastro, L. Shimizu, C. Wei, R. Shahir, A. Munoz, M. Antonio, B. San Andre, V. Harbeck, N. Martín, M.